Bachem Holding AG
SIX:BANB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
44.4
75.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CH |
|
Bachem Holding AG
SIX:BANB
|
5.6B CHF |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.3T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
237.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
166.8B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
83.6T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
37.4B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.1B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
277.8B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
38.3B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.9B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
20.2B EUR |
Loading...
|
Market Distribution
| Min | -13 700% |
| 30th Percentile | 34.9% |
| Median | 49.4% |
| 70th Percentile | 65.3% |
| Max | 137.7% |
Other Profitability Ratios
Bachem Holding AG
Glance View
In the heart of the Swiss pharmaceutical industry, Bachem Holding AG has carved out a distinct niche as a leading player in the peptide manufacturing landscape. Founded by Peter Grogg in 1971, Bachem has grown from a modest laboratory venture into a global powerhouse with an exceptional focus on peptides and oligonucleotide development. These biomolecules, small chains of amino acids, and nucleotides respectively, play crucial roles in modern therapeutics, acting as key components in drug design for treating various ailments. From its headquarters in Bubendorf, Switzerland, Bachem leverages cutting-edge technologies to enhance the purity and scalability of peptide production, meeting the demand from pharmaceutical and biotechnology companies worldwide. By establishing a robust supply chain and maintaining high standards of quality control, the company ensures the reliability and success of its partnerships. At the core of Bachem's business model is the offering of customized products and services tailored to client-specific needs, ranging from research-grade to commercial-scale production. The company generates revenue through long-term contracts and ongoing relationships with key players in the global pharmaceutical industry. As drug discovery advances, Bachem’s role in providing essential active pharmaceutical ingredients (APIs) becomes increasingly central, facilitating the development of novel therapies. The company also invests heavily in research and development to continuously refine its manufacturing processes and expand its service portfolio. By marrying scientific expertise with strategic foresight, Bachem not only anchors itself in the present pharmaceutical landscape but also positions itself for future growth in the biotechnology sector.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Bachem Holding AG is 31.2%, which is above its 3-year median of 30.8%.
Over the last 3 years, Bachem Holding AG’s Gross Margin has decreased from 31.6% to 31.2%. During this period, it reached a low of 29.6% on Jun 30, 2023 and a high of 32.2% on Dec 31, 2022.